What ails solid tumor radioimmunotherapy?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 2, 2006, Pages 81-84

  Divgi, Chaitanya ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN BINDING; BREAST CANCER; CANCER IMMUNOTHERAPY; DOSIMETRY; EDITORIAL; LYMPHOMA; PRIORITY JOURNAL; RADIATION SAFETY; RADIOIMMUNOTHERAPY; SOLID TUMOR; HUMAN; IMMUNOLOGY; METHODOLOGY; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 33744800572     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.81     Document Type: Editorial

References (20)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147.
2. Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: Current status and future perspectives. J Clin Oncol 2005;23:6394.
3. Chatal J.-F. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: The European Perspective. Cancer Biother Radiopharm 2006;21:1.
4. Goldenberg DM, DeLand F, Kim E, et al. Use of radio-labeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384.
5. Mach JP, Carrel S, Forni M, et al. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: A critical evaluation. N Engl J Med 1980;303:5.
6. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: Cancer cells compress intratumour vessels. Nature 2004;427:695.
7. Forero A, Meredith RF, Khazaeli MB, et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003;18:751.
8. Donnelly JG. Pharmacogenetics in cancer chemotherapy: Balancing toxicity and response. Ther Drug Monit 2004;26:231.
9. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1995;5(10 Suppl):3268S.
10. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med 2005;46(Suppl 1):141S.
11. Mulshine JL, Avis I, Treston AM, et al. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: Selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung. Int J Rad Appl Instrum B 1989;16:159.
12. 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004;45:1412.
13. 131I-anti-B1 antibody: Assessment of tumor dose response. J Nucl Med 2003;44:260.
14. O'Donoghue JA, Baidoo N, Deland D, et al. Hematologic toxicity in radioimmunotherapy: Dose-response relationships for I-131-labeled antibody therapy. Cancer Biother Radiopharm 2002;17:435.
15. Hu S, Shively L, Raubitschek A, et al. Minibody: A novel engineered anticarcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055.
16. Larson SM, El-Shirbiny AM, Divgi CR, et al. Single-chain antigen binding protein (sFv CC49): First human studies in colorectal carcinoma metastatic to liver. Cancer 1997;80:2458.
17. Knapp FF, Jr. Rhenium-188 - a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm 1998;13:337.
18. 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13:239.
19. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94:1332.
20. Schiller JH. Study design issues and early-stage non-small-cell lung cancer. Clin Cancer Res 2005;11(13 Pt 2):5030S.